Global and regional molecular epidemiology of HIV-1 during 1990-2024: systematic review, global survey, and analysis of prevalence.

Lancet Infect DisMay 19, 2026 (epub)
Clinical ResearchInfectious Diseases

Ayisha Khalid, Lucy Gettins, Lauren Scullion et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and global survey analyzed HIV-1 subtype distribution from 1990 to 2024, utilizing data from 1,395,222 samples across 154 countries. The study found that subtype C represented 48.7% of global infections in 2020-24, highlighting significant regional variations in HIV-1 diversity and prevalence.

Key findings

  • Subtype C accounted for 48.7% of global HIV-1 infections in 2020-24.
  • Subtype A represented 11.5% and subtype B 10.3% of infections during the same period.
  • Central Africa exhibited the greatest HIV-1 diversity among regions.
  • Notable increases in HIV-1 recombinants were observed in western and central Europe.

Why it matters

Understanding the global and regional distribution of HIV-1 subtypes is crucial for effective treatment strategies, vaccine development, and public health interventions. Clinicians must be aware of these variations to optimize patient care and surveillance efforts.

Source

PubMed · PMID 42155508

Published in Lancet Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.